Perspective: Will blood-informed design signal the fourth generation of cardiac assist devices?

Michael J Simmonds,Bente Thamsen,Salim E Olia,Antony P McNamee,Marcus Granegger,Hendrik Wurm,Keshava Rajagopal,David C McGiffin

DOI: https://doi.org/10.1016/j.healun.2024.08.011

2024-08-23

Abstract:Mechanical circulatory support devices have profoundly transformed the management of severe cardiothoracic disorders. While heart transplantation is the gold standard therapy for end stage heart disease, long-term mechanical support devices are a viable alternative for those ineligible and/or those awaiting organ availability. Major technological advancements were made over first five decades of development, resulting in improved durability and survival with reduced adverse events. However, gains have tapered recently for various complications (e.g., internal bleeding; multi-system organ failure) which collectively represent a significant proportion of disability and/or mortality. Further, in light of mature ventricular assist devices failing during clinical trials or even after clinical approval (Class I withdrawals), it is timely to consider: are our pre-clinical assessment protocols, vital in the design and development of mechanical circulatory support devices, providing a realistic and reliable profile of future clinical performance? This commentary explores this question and analyses development pathways through the lens of the various disciplines involved in the pre-clinical assessment of mechanical circulatory support technologies: limitations in approaches to benchtop blood testing, computational design and simulation, and animal testing are discussed as likely contributors to some of the common hemocompatibility-related adverse events. While it is acknowledged that some shortcomings are pragmatic in nature, possible solutions are presented that will only be realised through truly transdisciplinary and open approaches that challenge the current nature of medical device development. We suggest that these can and must be overcome to diminish hemocompatibility-related adverse events and will potentially demarcate the fourth-generation of cardiac assist devices.